Regulation of human g protein-coupled receptor
OwnerAlex Smolyarinventor
Life of this patent
Estimating the term…
Abstract
Reagents which regulate human G protein-coupled receptor (GPCR) and reagents which bind to human GPCR gene products can play a role in preventing, ameliorating, or correcting dysfunctions or diseases including, but not limited to, COPD, cardiovascular disorders, cancer, urinary disorders, obesity, diabetes, CNS disorders, liver disorders, kidney disorders, disorders of the secretory organs, asthma, a metabolic disease and hematological disorders.
Claims71
An isolated polynucleotide being selected from the group consisting of:
- a) a polynucleotide encoding a G protein-coupled receptor polypeptide comprising an amino acid sequence selected form the group consisting of:
- amino acid sequences which are at least about 50% identical to the amino acid sequence shown in SEQ ID NO:
- 2;
- and
- the amino acid sequence shown in SEQ ID NO:
- 2.
- b) a polynucleotide comprising the sequence of SEQ ID NO:
- 1;
- c) a polynucleotide which hybridizes under stringent conditions to a polynucleotide specified in (a) and (b) and encodes a G protein-coupled receptor polypeptide;
- d) a polynucleotide the sequence of which deviates from the polynucleotide sequences specified in (a) to (c) due to the degeneration of the genetic code and encodes a G protein-coupled receptor polypeptide;
- and
- e) a polynucleotide which represents a fragment, derivative or allelic variation of a polynucleotide sequence specified in (a) to (d) and encodes a G protein-coupled receptor polypeptide.
A cDNA encoding a polypeptide comprising the amino acid sequence shown in SEQ ID NO:
- 2.
An expression vector comprising a polynucleotide which encodes a polypeptide comprising the amino acid sequence shown in SEQ ID NO:
- 2.
A host cell comprising an expression vector which encodes a polypeptide comprising the amino acid sequence shown in SEQ ID NO:
- 2.
A purified polypeptide comprising the amino acid sequence shown in SEQ ID NO:2.
A fusion protein comprising a polypeptide having the amino acid sequence shown in SEQ ID NO:
- 2.
A method of producing a polypeptide comprising the amino acid sequence shown in SEQ ID NO:
- 2, comprising the steps of:
- culturing a host cell comprising an expression vector which encodes the polypeptide under conditions whereby the polypeptide is expressed;
- and
- isolating the polypeptide.
A method of detecting a coding sequence for a polypeptide comprising the amino acid sequence shown in SEQ ID NO:
- 2, comprising the steps of:
- hybridizing a polynucleotide comprising 11 contiguous nucleotides of SEQ ID NO:
- 1 to nucleic acid material of a biological sample, thereby forming a hybridization complex;
- and
- detecting the hybridization complex.
A method of detecting a polypeptide comprising the amino acid sequence shown in SEQ ID NO:
- 2, comprising the steps of:
- contacting a biological sample with a reagent that specifically binds to the polypeptide to form a reagent-polypeptide complex;
- and
- detecting the reagent-polypeptide complex.
A method of screening for agents which can modulate the activity of a human G protein-coupled receptor, comprising the steps of:
- contacting a test compound with a polypeptide comprising an amino acid sequence selected from the group consisting of:
- (1) amino acid sequences which are at least about 50% identical to the amino acid sequence shown in SEQ ID NO:
- 2 and (2) the amino acid sequence shown in SEQ ID NO:
- 2;
- and
- detecting binding of the test compound to the polypeptide, wherein a test compound which binds to the polypeptide is identified as a potential agent for regulating activity of the human G protein-coupled receptor.
A method of screening for agents which modulate an activity of a human G protein-coupled receptor, comprising the steps of:
- contacting a test compound with a polypeptide comprising an amino acid sequence selected from the group consisting of:
- (1) amino acid sequences which are at least about 50% identical to the amino acid sequence shown in SEQ D NO:
- 2 and (2) the amino acid sequence shown in SEQ ID NO:
- 2;
- and
- detecting an activity of the polypeptide, wherein a test compound which increases the activity of the polypeptide is identified as a potential agent for increasing the activity of the human G protein-coupled receptor, and wherein a test compound which decreases the activity of the polypeptide is identified as a potential agent for decreasing the activity of the human G protein-coupled receptor.
A method of screening for agents which modulate an activity of a human G protein-coupled receptor, comprising the steps of:
- contacting a test compound with a product encoded by a polynucleotide which comprises the nucleotide sequence shown in SEQ ID NO:
- 1;
- and
- detecting binding of the test compound to the product, wherein a test compound which binds to the product is identified as a potential agent for regulating the activity of the human G protein-coupled receptor.
A method of reducing activity of a human G protein-coupled receptor, comprising the step of:
- contacting a cell with a reagent which specifically binds to a product encoded by a polynucleotide comprising the nucleotide sequence shown in SEQ ID NO:
- 1, whereby the activity of a human G protein-coupled receptor is reduced.
A pharmaceutical composition, comprising:
- a reagent which specifically binds to a polypeptide comprising the amino acid sequence shown in SEQ ID NO:
- 2;
- and
- a pharmaceutically acceptable carrier.
A pharmaceutical composition, comprising:
- a reagent which specifically binds to a product of a polynucleotide comprising the nucleotide sequence shown in SEQ ID NO:
- 1;
- and
- a pharmaceutically acceptable carrier.
A pharmaceutical composition, comprising:
- an expression vector encoding a polypeptide comprising the amino acid sequence shown in SEQ ID NO:
- 2;
- and
- a pharmaceutically acceptable carrier.
A method of treating a G protein-coupled receptor dysfunction related disease, wherein the disease is selected from COPD, a cardiovascular disorders, cancer, a urinary disorder, obesity, diabetes, a CNS disorder, a liver disorder, a kidney disorder, a disorder of the secretory organs, asthma, a metabolic disease or a hematological disorder comprising the step of:
- administering to a patient in need thereof a therapeutically effective dose of a reagent that modulates a function of a human G protein-coupled receptor, whereby symptoms of the G protein-coupled receptor disfunction related disease are ameliorated.
Dependencies are inferred from the claim text.